Disc Medicine Advances Pipeline with Key Data, Eyes 2026 Milestones

Event summary

  • Disc Medicine reported $791M in cash reserves as of Q4 2025, up from $490M in 2024, with runway into 2029.
  • Phase 3 APOLLO study for bitopertin in EPP expected to complete enrollment in March 2026 with topline data in Q4 2026.
  • Phase 2 data for DISC-0974 in myelofibrosis anemia showed meaningful responses, regardless of baseline transfusion status or JAK inhibitor use.
  • Phase 1b study of DISC-3405 in sickle cell disease initiated in Q4 2025, with initial data expected in 2H 2026.

The big picture

Disc Medicine is advancing its pipeline with key clinical data while navigating regulatory hurdles for bitopertin. The company's strong cash position provides flexibility as it pursues multiple hematologic disease indications, positioning it within the competitive landscape of rare disease therapeutics. The strategic focus on heme biosynthesis and iron homeostasis pathways underscores its commitment to addressing unmet needs in serious hematologic diseases.

What we're watching

Regulatory Pathway
Whether the Phase 3 APOLLO study will position bitopertin for traditional FDA approval by mid-2027.
Pipeline Momentum
The pace at which DISC-0974 and DISC-3405 progress through clinical trials, particularly in myelofibrosis and sickle cell disease.
Financial Runway
How Disc Medicine manages its $791M cash position to support operations and potential commercialization through 2029.